Related Experiment Videos
CD56+ NK lymphomas: clinicopathological features and prognosis
British Journal of Haematology
|June 1, 1997
Summary
CD56+ natural killer (NK) cell lymphomas present in localized or multi-organ forms, with distinct clinical and prognostic features. Current chemotherapy shows limited efficacy, necessitating novel treatment strategies for these rare lymphomas.
Area of Science:
- Hematology
- Oncology
- Immunology
Background:
- CD56 is a surface marker identifying a subset of lymphomas originating from natural killer (NK) cells.
- Understanding the clinicopathologic and prognostic features of CD56+ NK lymphomas is crucial for patient management.
Purpose of the Study:
- To retrospectively analyze 24 cases of CD56+ NK lymphoma/leukemia.
- To define the distinct clinicopathologic and prognostic characteristics of this lymphoma subtype.
Main Methods:
- Retrospective analysis of 24 CD56+, CD3- lymphoma cases.
- Review of clinical presentation, site of involvement, treatment response, and survival data.
Main Results:
- Two main presentations identified: localized (predominantly nasal, n=20) and multi-organ (n=4).
- Localized disease showed better outcomes with chemotherapy (75% remission, 12-month median survival) compared to multi-organ disease (25% remission, 2-month median survival).
- Overall median survival was poor (11 months), with conventional chemotherapy demonstrating limited effectiveness.
Conclusions:
- CD56+ NK lymphomas exhibit distinct localized and multi-organ disease patterns with differing prognoses.
- Current chemotherapy regimens are largely ineffective, highlighting the urgent need for innovative therapeutic approaches to improve patient outcomes.